NCT02768662View on ClinicalTrials.gov

A 6-Month Extension Study of OTO-104 in Meniere's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Meniere's Disease
Interventions
DRUG

OTO-104

Single intratympanic injection of 12 mg OTO-104

Trial Locations (1)

92121

Many sites in Europe. Refer to the contact info listed below., San Diego

Sponsors

Lead Sponsor

Otonomy, Inc.
All Listed Sponsors
lead

Otonomy, Inc.

INDUSTRY